What is the 13F Pro Quality Score for CPRX?

13F Pro ranks CATALYST PHARMACEUTICALS, INC. (CPRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CPRX's current score at https://13fpro.ai/research/CPRX (free sign-up required for the full ranking).

Which hedge funds own the most CPRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CPRX include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CPRX as soon as new 13F filings post.

Where does 13F Pro source CPRX data?

All CATALYST PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. CATALYST PHARMACEUTICALS, INC. files with the SEC under CIK 1369568. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CPRX in?

CATALYST PHARMACEUTICALS, INC. (CPRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives CPRX's revenue?

Per CATALYST PHARMACEUTICALS, INC.'s latest 10-Q filed with the SEC on 2026-05-11, the biggest revenue drivers are: FIRDAPSE® ($98.9M, +18.1% YoY); AGAMREE® ($36.7M, +66.6% YoY); FYCOMPA® ($13.8M, -61.3% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/CPRX.

What are CPRX's largest expenses?

CATALYST PHARMACEUTICALS, INC.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($49.3M, +5.1% YoY); Amortization of intangible assets ($9.7M, +3.9% YoY); Research and development ($2.7M, -31.5% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is CPRX research updated on 13F Pro?

CPRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CATALYST PHARMACEUTICALS, INC.(CPRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1369568 CPRX stock profile & AI dashboard →

13F Pro Quality Score

78.7/100

Rank #65 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

83.4/100

Profitability

93.9/100

Balance Sheet

96.8/100

Earnings Quality

92.1/100

Free Cash Flow

89.5/100

Institutional Flow

67.4/100

Revenue Scale

39.3/100

Dilution Risk

28.5/100

CPRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CATALYST PHARMACEUTICALS, INC. (CPRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CPRX at 78.7/100 on a 32-signal composite quality model, placing it at rank #65 of 2,879 stocks — the top 5% of the AI-ranked universe. CPRX scores in the top quartile across balance sheet strength (96.8), profitability (93.9), earnings quality (92.1). Areas of concern include revenue scale (39.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CATALYST PHARMACEUTICALS, INC. reports quarterly revenue of $149.4M, net income of $63.7M, an operating margin of 49.0%. Top institutional holders of CPRX by reported 13-F value include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CPRX trades on the Nasdaq exchange and files with the SEC under CIK 1369568. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CATALYST PHARMACEUTICALS, INC. directly from SEC EDGAR. CATALYST PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 8 and 90 since 2021, currently 78.7 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about CATALYST PHARMACEUTICALS, INC.

Quirks, history, and lore behind CPRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in Florida.
2
The Numbers
Annual revenue in the range of $200–300 million — modest by pharma standards, but built almost entirely on a single rare-disease franchise with strong pricing power.
3
The History
Founded in the early 2000s, the company spent years developing drugs for rare neuromuscular conditions before finally landing an FDA-approved blockbuster that put it on the map.
4
The Secret
Its core drug targets Lambert-Eaton myasthenic syndrome (LEMS) — a rare autoimmune disorder so obscure most doctors have never seen a case — giving it a near-monopoly in a tiny but lucrative market.
5
The Lore
The active ingredient in its flagship product, amifampridine, had been used off-label for decades in Europe before this company shepherded it through the rigorous FDA approval process for the U.S. market.
6
The Giveaway
Its FDA-approved drug Firdapse treats LEMS, and the company's name is basically a metaphor for sparking a chemical reaction — fitting for a firm that jumpstarted a forgotten molecule's second life.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving CPRX's Business? Latest 10-Q Breakdown

AI-extracted from CATALYST PHARMACEUTICALS, INC.'s 10-Q filed 2026-05-11 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Catalyst reported Q1 2026 net income of $63.7M on total revenues of $149.4M, driven by FIRDAPSE® sales growth of 18.1% YoY and AGAMREE® growth of 66.6% YoY, offset by FYCOMPA® decline of 61.3% due to generic competition.

Biggest Revenue Drivers

Total revenue: $149.4M+5.6% YoY

FIRDAPSE®$98.9M+18.1% YoY

Increased sales volumes from expanded patient population and higher daily dosing following May 2024 FDA approval increasing maximum daily dose from 80mg to 100mg.

AGAMREE®$36.7M+66.6% YoY

Strong ramp following U.S. commercial launch in March 2024 and ongoing patient adoption for DMD treatment.

FYCOMPA®$13.8M-61.3% YoY

Significant decline due to generic competition following patent expiration in May 2025; company ceased marketing efforts end of 2025.

License and other revenue$0.047M

Consisted of immaterial royalties from sublicensee agreements.

Largest Expense Items

Selling, general and administrative$49.3M+5.1% YoY

Increase primarily due to consulting fees for business development initiatives, offset partly by reduced FYCOMPA® commercialization expenses.

Amortization of intangible assets$9.7M+3.9% YoY

Amortization of FYCOMPA® (5-year), RUZURGI® (14.5-year), and AGAMREE® (10.5-year) product rights over estimated useful lives.

Research and development$2.7M-31.5% YoY

Lower preclinical and clinical trial expenses; company continues development activities for FIRDAPSE® and AGAMREE® additional indications.

Watch Items from the Filing

Customer concentration: Customer A represented 90.1% of Q1 2026 net product revenue (exclusive distributor), up from 74.0% YoY; significant dependence on single distributor for FIRDAPSE® and AGAMREE® U.S. sales.
Merger pending: On May 6, 2026, company agreed to be acquired by Angelini Pharma at $31.50/share; closing expected Q3 2026; subject to regulatory approvals and $155.5M termination fee if deal fails.
FIRDAPSE® generic litigation: Settled with Hetero on May 6, 2026 for $11M litigation avoidance fee; generic entry blocked until January 2035; all major generic filers (Teva, Lupin, Inventia, Hetero) now settled.
FYCOMPA® revenue cliff: Revenues collapsed 61% YoY due to three approved generic tablets and one generic oral suspension; company ceased marketing end of 2025; further revenue declines expected.
AGAMREE® supply transition: Company transitioning from Santhera to own U.S. manufacturer (estimated completion end 2026); also pursuing additional indications and life cycle management opportunities.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$149.4M

Net Income

Q1 2026

$63.7M

Free Cash Flow

Q1 2026

$59.6M

Operating Margin

Q1 2026

49.0%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+19.8% YoY

$589.0MFY 2025

FY20 $119.1MFY23 $398.2MFY24 $491.7MFY25 $589.0M

Net Income

+30.8% YoY

$214.3MFY 2025

FY20 $75.0MFY23 $71.4MFY24 $163.9MFY25 $214.3M

Operating Income

+32.1% YoY

$257.8MFY 2025

FY20 $41.3MFY23 $86.8MFY24 $195.1MFY25 $257.8M

EPS (Diluted)

+28.2% YoY

$1.68FY 2025

FY20 $0.71FY23 $0.63FY24 $1.31FY25 $1.68

Total Assets

+29.7% YoY

$1.10BFY 2025

FY20 $192.4MFY23 $470.1MFY24 $851.4MFY25 $1.10B

Op. Cash Flow

-13.0% YoY

$208.7MFY 2025

FY20 $45.0MFY23 $143.6MFY24 $239.8MFY25 $208.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2019	FY 2017
Revenue	$589.0M +19.8%	$491.7M +23.5%	$398.2M +234.4%	$119.1M +16.4%	$102.3M	$0.00
Net Income	$214.3M +30.8%	$163.9M +129.5%	$71.4M -4.8%	$75.0M +135.2%	$31.9M +273.1%	$-18.4M
Operating Income	$257.8M +32.1%	$195.1M +124.8%	$86.8M +110.2%	$41.3M +29.8%	$31.8M +270.4%	$-18.7M
EPS (Diluted)	$1.68 +28.2%	$1.31 +107.9%	$0.63 -11.3%	$0.71 +136.7%	$0.30	—
Total Assets	$1.10B +29.7%	$851.4M +81.1%	$470.1M +144.4%	$192.4M +71.2%	$112.4M +31.6%	$85.4M
Operating Cash Flow	$208.7M -13.0%	$239.8M +67.0%	$143.6M +218.9%	$45.0M +30.1%	$34.6M +351.9%	$-13.7M

Get alerted when CPRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CATALYST PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CPRX

BlackRock, Inc.
$464.9M18,774,530 sh
STATE STREET CORP
$169.9M6,863,060 sh
VANGUARD CAPITAL MANAGEMENT LLC
$126.8M5,122,666 sh
AMERICAN CENTURY COMPANIES INC
$102.5M4,138,416 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$97.6M3,943,600 sh
DIMENSIONAL FUND ADVISORS LP
$84.9M3,429,615 sh
BANK OF AMERICA CORP /DE/
$75.2M3,036,546 sh
GEODE CAPITAL MANAGEMENT, LLC
$73.6M2,972,402 sh
MORGAN STANLEY
$66.5M2,687,299 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$61.3M2,475,467 sh

Fund	Value	Shares
BlackRock, Inc.	$464.9M	18,774,530
STATE STREET CORP	$169.9M	6,863,060
VANGUARD CAPITAL MANAGEMENT LLC	$126.8M	5,122,666
AMERICAN CENTURY COMPANIES INC	$102.5M	4,138,416
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$97.6M	3,943,600
DIMENSIONAL FUND ADVISORS LP	$84.9M	3,429,615
BANK OF AMERICA CORP /DE/	$75.2M	3,036,546
GEODE CAPITAL MANAGEMENT, LLC	$73.6M	2,972,402
MORGAN STANLEY	$66.5M	2,687,299
VANGUARD PORTFOLIO MANAGEMENT LLC	$61.3M	2,475,467

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CPRX on your watchlist

Track score changes the day CATALYST PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CPRX a good stock to buy?

13F Pro's AI-powered analysis of CATALYST PHARMACEUTICALS, INC. (CPRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CPRX are available on the CPRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CPRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CPRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CATALYST PHARMACEUTICALS, INC.'s investment landscape.